A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

NCT00712322 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

35

Enrollment

INDUSTRY

Sponsor class

Stopped Due to extremely difficult enrollment.

Conditions

Neurogenic Detrusor Overactivity

Interventions

DRUG: Darifenacin

Sponsor

Warner Chilcott